United States · Platforms & data · Yahoo Finance

KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial

Published by Yahoo Finance · United States 9 h ago

PITTSBURGH, November 06, 2026--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

The Motley Fool

Franklin (BEN) Q4 2026 Earnings Call Transcript

Seeking Alpha

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Investing.com

Haiti PM says gang leader Mathias Saintil dead

MarketWatch

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

CNBC

Nasdaq drops into correction territory — here’s what typically happens next

TheStreet